Extensive Experience in Public Companies, M&A, Financings and IR
DENVER, Nov. 17 /PRNewswire-FirstCall/ -- Global Med Technologies(R), Inc. ("Global Med" or "the Company") (OTC Bulletin Board: GLOB), an international e-Health, medical information technology company, today announced the appointment of Karen Davis to the position of Chief Financial Officer. Ms. Davis officially assumes the position of CFO today.
Ms. Davis brings to the Company her strong business drive and diversified experience as a CFO. Her background includes a BS in Business Administration from California State University, a CPA, 10 years in public accounting, and 15 years of CFO experience, including 8 years with public companies. Ms. Davis also has broad IR experience, having served 3 years as Director of Financial Reporting and Investor Relations for an NYSE-listed company. In addition, Ms. Davis has extensive M&A experience, as well as experience in scaling companies through organic growth and acquisition.
Ms. Davis will report directly to Mick Ruxin, M.D., Chairman and Chief Executive Officer of Global Med Technologies, Inc. In his comments about this key appointment, Dr. Ruxin stated, "As a direct result of our dramatic growth into a leading global entity in the blood supply safety arena, and our expansion into other biomedical areas, the need for a CFO with extensive knowledge in public accounting, mergers and acquisitions, sophisticated financing and investor relations became mandatory. Such a highly experienced senior executive will play a crucial role in attaining our objectives of profitable, rapid growth and moving to a listed exchange. I am extremely pleased to have an individual with the knowledge and abilities tempered by the experience of Karen Davis join our Company. Karen is a great fit for Global Med, and with her background, she will truly add value to our strategy, our processes and our management team."
Commenting on her appointment, Ms. Davis said, "I am very excited to join a dynamic growth company in a global market." Ms. Davis continued, "Also, I am particularly pleased to be a part of a creative management team that is truly making a difference in the blood bank, hospital, laboratory and biologic software industry throughout the world."
About Global Med Technologies, Inc.
Global Med Technologies(R), Inc. is an international medical software company which develops regulated and non-regulated software products and services for the healthcare industry. As a leading provider of blood and laboratory software applications and services, Global Med's products are deployed in 20 countries and serve over 1,600 transfusion centers, blood banks and laboratories.
Global Med's U.S. division, Wyndgate Technologies(R), provides Vein-to-Vein(R) tracking through its Donor Doc(TM), SafeTrace(R), SafeTrace Tx(R) and ElDorado Donor(TM) software products. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply.
Global Med's European subsidiary, Inlog, SA, is a leading provider of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally. Inlog's products include EdgeBlood*, EdgeTrack*, EdgeCell, EdgeLab and Sapa/SapaNet.
Global Med's U.S. division, eDonor(R), provides a web-based donor relationship management system that integrates recruitment, scheduling, retention and fulfillment for national as well as local community blood centers and hospitals. eDonor's products and services are designed to complement Global Med's strong line of international blood management and laboratory information software and service solutions.
Global Med's U.S. subsidiary, PeopleMed(R), Inc., provides cost-effective customized software validation, consulting and compliance solutions to hospitals and donor centers.
For more information about Global Med's products and services, please call 800-996-3428 or visit www.globalmedtech.com, www.peoplemed.com, www.inlog.com, www.eDonor.com, and www.wyndgate.com.
*FDA 510(k) clearance required prior to sales in the U.S.
This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release.
SOURCE Global Med Technologies, Inc.